Revolution Medicines (RVMD)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
+$0.57 (+1.21%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0

About

Business overview of Revolution Medicines (RVMD)
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs.

Key Insights

Critical company metrics and information
  • Share Price

    $48.07
  • Market Cap

    $8.09 Billion
  • Total Outstanding Shares

    168.22 Million Shares
  • Total Employees

    490
  • Dividend

    No dividend
  • IPO Date

    February 13, 2020
  • SIC Description

    Biological Products, (no Disgnostic Substances)
  • Homepage

    https://www.revmed.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Cash Flow From Investing Activities, Continuing$-541.89 Million
Net Cash Flow, Continuing$-156.64 Million
Net Cash Flow From Financing Activities$924.96 Million
Net Cash Flow From Investing Activities$-541.89 Million
Net Cash Flow From Financing Activities, Continuing$924.96 Million
Net Cash Flow$-156.64 Million
Net Cash Flow From Operating Activities$-539.71 Million
Net Cash Flow From Operating Activities, Continuing$-539.71 Million

Income Statement

October 1, 2023 to September 30, 2024
MetricValue
Income Tax Expense/Benefit$343000.00
Diluted Earnings Per Share$3.66
Research and Development$553.19 Million
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0.00
Preferred Stock Dividends And Other Adjustments$0.00
Other Operating Expenses$95.75 Million
Revenues$742000.00
Diluted Average Shares$341.23 Million
Operating Expenses$653.94 Million
Net Income/Loss Available To Common Stockholders, Basic$-567.06 Million
Basic Earnings Per Share$3.66
Income/Loss From Continuing Operations After Tax$-567.06 Million
Net Income/Loss Attributable To Parent$-567.06 Million
Income/Loss From Continuing Operations Before Tax$-566.72 Million
Basic Average Shares$341.23 Million
Net Income/Loss Attributable To Noncontrolling Interest$0.00
Net Income/Loss$-567.06 Million
Operating Income/Loss$-653.20 Million
Nonoperating Income/Loss$86.48 Million

Balance Sheet

October 1, 2023 to September 30, 2024
MetricValue
Current Assets$1.58 Billion
Noncurrent Liabilities$85.83 Million
Assets$1.76 Billion
Accounts Payable$24.46 Million
Equity Attributable To Noncontrolling Interest$0.00
Liabilities$196.69 Million
Fixed Assets$24.81 Million
Equity$1.57 Billion
Equity Attributable To Parent$1.57 Billion
Other Non-current Assets$102.11 Million
Noncurrent Assets$183.86 Million
Liabilities And Equity$1.76 Billion
Other Current Liabilities$86.41 Million
Intangible Assets$56.94 Million
Current Liabilities$110.86 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.